McCann Health has launched a new consultancy, Consulting at McCann Health, with two objectives. The first: consolidate its health consulting agencies. And the…

When Gilead's hep C drugs hit the market, their older rivals went into a tailspin. Now, it's Gilead's time to suffer. The hep C market is once…

Johnson & Johnson has a new indication for anti-inflammatory med Stelara--and not a moment too soon.

India's FMRAI union is calling for a mass strike by pharma sales reps in November as protests over working practices gather strength.

It’s been a while since Novartis’ rare disease med Ilaris picked up a label-expansion boost, but now the Swiss drugmaker has three of them to show for its…

With brand-new hiked-up sales forecasts for its newest meds, Bayer is hoping for a home run from prostate cancer-fighter Xofigo--and it's counting on a…

Sanofi and Regeneron’s next wannabe blockbuster is officially in regulators’ hands--but with the candidate tapped for a speedy review process, it may not stay…

New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to…